14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan. (linkinghub.elsevier.com)

Authors: Sakakida T … Masuishi T Journal: The Lancet Published: 2026-10-24 DOI: https://doi.org/10.1016/S0140-6736(26)01782-4